Cargando…
Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma
• A case of grade 2 endometrial adenocarcinoma in a young woman desiring fertility-sparing treatment; • Successful conservative management of refractory endometrial adenocarcinoma with dual progestin therapy; • A brief review of conservative management in endometrial adenocarcinoma;
Autores principales: | Newtson, A.M., Pakish, J.B., Nick, A.M., Westin, S.N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554929/ https://www.ncbi.nlm.nih.gov/pubmed/28831417 http://dx.doi.org/10.1016/j.gore.2017.08.001 |
Ejemplares similares
-
Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019) -
Pushing the envelope: expanding fertility sparing treatment of endometrial cancer
por: Stewart, Katherine Ikard, et al.
Publicado: (2020) -
Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021) -
Fertility-Sparing Treatment in Young Patients With Grade 2 Presumed Stage IA Endometrioid Endometrial Adenocarcinoma
por: Yu, Mei, et al.
Publicado: (2020) -
Fertility-sparing surgery for patients with low-grade endometrial stromal sarcoma
por: Xie, Weimin, et al.
Publicado: (2016)